HC Wainwright Reiterates Buy Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The brokerage currently has a $32.00 price objective on the stock.

A number of other analysts also recently issued reports on KURA. JMP Securities raised their price target on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a report on Wednesday, January 31st. Wedbush restated an outperform rating and set a $37.00 price target on shares of Kura Oncology in a report on Wednesday, February 28th. Finally, StockNews.com downgraded shares of Kura Oncology from a hold rating to a sell rating in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Kura Oncology presently has an average rating of Moderate Buy and an average price target of $28.28.

Kura Oncology Price Performance

Kura Oncology stock traded up $0.66 during midday trading on Monday, reaching $18.19. The company had a trading volume of 2,001,202 shares, compared to its average volume of 1,353,667. The company has a market capitalization of $1.39 billion, a P/E ratio of -8.82 and a beta of 0.85. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The firm's fifty day simple moving average is $20.78 and its 200-day simple moving average is $15.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the business earned ($0.49) earnings per share. As a group, equities analysts anticipate that Kura Oncology will post -2.35 EPS for the current year.

Insider Activity at Kura Oncology

In related news, COO Kathleen Ford sold 1,496 shares of the business's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company's stock, valued at $384,515.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, COO Kathleen Ford sold 1,496 shares of the business's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company's stock, valued at $384,515.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares in the company, valued at $856,055.40. The disclosure for this sale can be found here. Insiders sold a total of 96,919 shares of company stock valued at $1,946,415 over the last ninety days. Insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in shares of Kura Oncology by 40.4% in the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company's stock valued at $72,000 after purchasing an additional 1,449 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kura Oncology by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company's stock valued at $124,000 after buying an additional 6,692 shares during the period. Saxon Interests Inc. purchased a new position in shares of Kura Oncology during the first quarter valued at approximately $201,000. Pale Fire Capital SE purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $92,000. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Kura Oncology by 12.2% during the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company's stock valued at $109,000 after buying an additional 1,301 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.